Anemia: 

Study: To evaluate the efficacy and safety of a 1.02 g course of IV ferumoxytol, administered as two doses of 510 mg each, compared with placebo (normal saline) for the treatment of iron deficiency anemia (IDA)

Description: A Phase III, Randomized, Double-Blind, Placebo-Controlled Trial of Ferumoxytol for the Treatment of Iron Deficiency Anemia

Entry Criteria:

• Males and females >18 years of age, Subjects with IDA defined as: a) hemoglobin <10.0 g/dL b) TSAT <20%
• Female subjects of childbearing potential who are sexually active must be on an effective method of birth control for at least 1 month prior to screening
• Subjects who have a history of unsatisfactory oral iron therapy or in whom oral iron cannot be used

Study Duration: The duration of subject participation in the study will be approximately 7 weeks: • Screening Period: 2 weeks • Treatment Period: 5 weeks

Compensation: Compensation is available but compensation will very based on visits completed

Contact Nina, CRC: (727) 724-9730

Home | About | Products | News | Contact